FindTrial
Sign In

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN I & ATTAIN II)

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN I & ATTAIN II)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000324617
Acronym
ATTAIN I & ATTAIN II
Enrollment
750
Registered
2005-09-06
Start date
2005-02-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Telavancin 10 mg/kg q 24 hours IV

Sponsors

Theravance, Inc.
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Diagnosis of hospital acquired pneumonia.

Exclusion criteria

More than 24 hours of prior therapy unless a treatment failure. Pregnancy.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026